wie gewonnen so zerronnen:
Biogen plunges 30% after FDA panel votes against Alzheimer's drug
(Reuters) - Biogen Inc's <BIIB.O> shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.
Wall Street analysts largely believe the panel's near-unanimous votes against the drug, aducanumab, make it difficult for the FDA to go against the panel.
...
https://finance.yahoo.com/news/biogen-pl...21812.html
Biogen plunges 30% after FDA panel votes against Alzheimer's drug
(Reuters) - Biogen Inc's <BIIB.O> shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.
Wall Street analysts largely believe the panel's near-unanimous votes against the drug, aducanumab, make it difficult for the FDA to go against the panel.
...
https://finance.yahoo.com/news/biogen-pl...21812.html
![[Bild: BIIBc1dl1543.png]](https://finviz.com/publish/110920/BIIBc1dl1543.png)
__________________